Pfizer-backed VitaDAO spins out biotech company

VitaDAO, which funds longevity research, announced the $300,000 financing of a biotechnology company, the DAO’s first such investment

by Jack Kubinec /

October 9, 2023 07:00 am

PowerUp/Shutterstock modified by Blockworks

VitaDAO is announcing the launch of Matrix Biosciences, a biotechnology company led by University of Rochester anti-aging researcher Vera Gorbunova. The launch comes with $300,000 in initial financing, with more funding to come in early 2024.

The company will expand on Gorbunova’s research on the long life spans and cancer resistance of naked mole rats and examine whether a compound found in the rats could improve human lifespan.

Launched in 2021, VitaDAO funds “longevity” research aimed at extending human life. The DAO currently funds 20 projects, primarily focused on potential “moonshot” contributions to longevity science. Todd White, a VitaDAO core contributor, compared the DAO to an endowment fund, because members don’t take a profit from the research and all revenue is sent to the DAO treasury to fund other projects.

Newsletter

Subscribe to The Breakdown

The DAO closed a $4 million funding round earlier this year, headlined by an investment from Pfizer Ventures.

VitaDAO invests in “valley of death”-stage ideas where research is still unproven, White said, adding that Pfizer once put significant resources into an early-stage investment team but judged such investments too risky before investing in VitaDAO.

“They realized we were doing what they were trying to do, but we were doing it better and at a fraction of the cost. And so this was kind of this real sort of Web3 awakening for Pfizer,” White said.

Being a community of researchers, VitaDAO has positioned itself within the “decentralized science” movement and a growing interest in DAOs as research funding tools.

White said the DAO has struggled to ingratiate itself into the university milieu as blockchain technology struggles to rehab its image in the wake of the FTX collapse. But White feels like the niche field of longevity research shares an ethos with crypto.

Both worlds believe “we’re not going to go through this traditional thing. This is stupid. There’s a whole bunch of impediments here,” White said. “We’re retesting all the original assumptions.”

Get the news in your inbox. Explore Blockworks newsletters:

The Breakdown: Decoding crypto and the markets. Daily.
0xResearch: Alpha in your inbox. Think like an analyst.

Tags

Newsletter

The Breakdown

Decoding crypto and the markets. Daily, with Byron Gilliam.

Upcoming Events

Digital Asset Summit 2026

Javits Center North | 445 11th Ave

Tues - Thurs, March 24 - 26, 2026

Blockworks’ Digital Asset Summit (DAS) will feature conversations between the builders, allocators, and legislators who will shape the trajectory of the digital asset ecosystem in the US and abroad.

buy tickets learn more

recent research

Research

Kinetiq Protocol: From LST Infrastructure to HIP-3 Deployer

Kinetiq has established itself as Hyperliquid's dominant liquid staking protocol, holding 82.5% of LST market share with $610M in TVL. The protocol is now expanding beyond its kHYPE staking core into higher take-rate verticals: iHYPE for institutional custody rails, Launch for HIP-3 capital formation, and Markets for builder-deployed perpetuals. We view Markets, launching Jan. 12, as the highest-potential product line given its mechanically scalable, activity-linked unit economics. Near-term revenue remains anchored by kHYPE's KIP-2 fee schedule (~$1.6M annualized), while Markets provides embedded optionality if HIP-3 economics normalize post-Growth Mode. KNTQ's setup is relatively clean: zero insider unlocks until November 2026, 6.2% buyback yield from staking revenue, and cleared airdrop overhang. Risks center on unproven Markets execution, declining kHYPE TVL despite ongoing incentives, and competition from Hyperliquid's native initiatives.

by Shaunda Devens